$1,060,000 of BIOGEN lobbying was just disclosed, from Q2 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share H.R.6130/S.3267, ASAP Act, to provide coverage for blood based biomarker Alzheimer's disease diagnosis H.R.3747, AADAPT Act, to provide for training for primary care for screening, detection and diagnosis for Alzheimer's disease Issues related to the Food and Drug Administration including PDUFA, druga reviews, approval pathways, and clinical trials H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review Voucher Program Postpartum Depression public policy on screening, detection and education Discussions regarding drug cost and pricing policy and issues related to the Medicaid 340B program, no specific bill. Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies. H.R.4317, PBM Reform Act of 2025 S.3345, PBM Price Transparency and Accountability Act H.R.6837, to amend the Emloyee Retirement Income Security Act of 1974 to ensure PBMs are considered fiduciaries Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. H.R.1492/S.832, EPIC Act, equalizes the negotation period between small-molecule and biologic candidates under the Drig Price Negotiation laws H.R.946, ORPHAN CURES Act Issues related to tax reform and tax policy, implementation of Tax Cuts and Jobs Act of 2017 (P.L.115-97), policies related to OECD on the taxation of global income. Trade-related public policy around tariffs and intellectual property, no related bills"
You can find more data on corporate lobbying on Quiver Quantitative.
BIIB Congressional Stock Trading
Members of Congress have traded $BIIB stock 6 times in the past 6 months. Of those trades, 5 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $BIIB stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 2 purchases worth up to $30,000 on 06/05, 01/30 and 0 sales.
- REPRESENTATIVE MARIA ELVIRA SALAZAR has traded it 4 times. They made 3 purchases worth up to $130,000 on 05/12, 05/11 and 1 sale worth up to $50,000 on 06/02.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
BIIB Insider Trading Activity
BIIB insiders have traded $BIIB stock on the open market 3 times in the past 6 months. Of those trades, 1 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $BIIB stock by insiders over the last 6 months:
- PRIYA SINGHAL (Head of Development) has made 0 purchases and 2 sales selling 3,408 shares for an estimated $665,664.
- NICOLE MURPHY (Head of Pharm Ops and Tech) purchased 3 shares for an estimated $585
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
BIIB Hedge Fund Activity
We have seen 465 institutional investors add shares of BIIB stock to their portfolio, and 366 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 3,381,678 shares (+35.9%) to their portfolio in Q1 2026, for an estimated $619,963,027
- POINT72 ASSET MANAGEMENT, L.P. removed 2,003,575 shares (-71.2%) from their portfolio in Q1 2026, for an estimated $367,315,404
- BLACKROCK, INC. added 1,163,231 shares (+7.9%) to their portfolio in Q1 2026, for an estimated $213,255,139
- MILLENNIUM MANAGEMENT LLC removed 1,031,622 shares (-91.7%) from their portfolio in Q1 2026, for an estimated $189,127,261
- BARCLAYS PLC removed 753,533 shares (-57.7%) from their portfolio in Q1 2026, for an estimated $138,145,204
- WELLINGTON MANAGEMENT GROUP LLP removed 589,628 shares (-16.6%) from their portfolio in Q1 2026, for an estimated $108,096,501
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 521,385 shares (-78.8%) from their portfolio in Q1 2026, for an estimated $95,585,512
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
BIIB Analyst Ratings
Wall Street analysts have issued reports on $BIIB in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 06/29/2026
- Evercore ISI Group issued a "Outperform" rating on 05/15/2026
- Guggenheim issued a "Buy" rating on 04/30/2026
- Oppenheimer issued a "Outperform" rating on 01/30/2026
To track analyst ratings and price targets for BIIB, check out Quiver Quantitative's $BIIB forecast page.
BIIB Price Targets
Multiple analysts have issued price targets for $BIIB recently. We have seen 19 analysts offer price targets for $BIIB in the last 6 months, with a median target of $225.0.
Here are some recent targets:
- Matthew Harrison from Morgan Stanley set a target price of $222.0 on 07/08/2026
- Brian Abrahams from RBC Capital set a target price of $242.0 on 07/07/2026
- Ami Fadia from Needham set a target price of $256.0 on 06/29/2026
- Salim Syed from Mizuho set a target price of $221.0 on 06/15/2026
- David Amsellem from Piper Sandler set a target price of $225.0 on 05/15/2026
- Geoff Meacham from Citigroup set a target price of $200.0 on 05/01/2026
- Yatin Suneja from Guggenheim set a target price of $260.0 on 04/30/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
